Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Qing ZhouSamantha O PerakisPeter UlzSumitra MohanJakob M RiedlEmina TalakicSigurd LaxMartin TötschGerald HoeflerThomas BauernhoferMartin PichlerArmin GergerJochen B GeiglEllen HeitzerMichael R SpeicherPublished in: Genome medicine (2020)
Non-invasive analyses of cell-free DNA from patients undergoing treatment with bevacizumab enabled the tracking of evolving tumor genomes and helped identify a recurrent focal SCNA of clinical relevance. Here, we describe a novel resistance mechanism against a widely applied treatment in patients with mCRC which will impact the clinical management of patients.
Keyphrases